Clinical Scorecard: Scaling CRISPR Gene Correction for Sickle Cell Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Scaling CRISPR Gene Correction for Sickle Cell Disease |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Clinical-scale cell manufacturing; products have been manufactured for two participants in an ongoing Phase I/II clinical trial. The therapy is investigational. |
Key Highlights
- CRISPR_SCD001 is designed to repair the disease-causing HBB mutation rather than add an anti-sickling gene or edit a regulatory region to increase fetal hemoglobin.
- The manufacturing process includes cell culture, electroporation with CRISPR-Cas9 and corrective DNA, washing, cryopreservation, and product testing before release.
- Across full-scale lots, average CD34-positive cell purity was 89% and viability was 84%; an average of 22% of HBB alleles were corrected.
- In vitro differentiated red blood cells showed sickle hemoglobin decreasing from 89% to 22%, with adult and fetal hemoglobin reaching 39% and 40%, respectively.
- Products have been manufactured for two participants in an ongoing Phase I/II trial assessing safety, engraftment, and persistence of corrected cells.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Editing was detected at one previously identified off-target intergenic site at an average frequency of 4%.
- No HBB–off-target translocations were detected above the assay's 0.01% detection threshold; normal karyotypes were reported in the two lots assessed.
- In mice, edited human cells engrafted at lower levels than unedited controls, but remained present in multiple hematopoietic tissues after 16 weeks. Investigators reported no noteworthy treatment-related toxicity or abnormal tissue changes.
Patient & Prescribing Data
People with sickle cell disease; the article reports that products were manufactured for two participants in an ongoing Phase I/II trial.
The therapy uses a patient's own mobilized peripheral blood CD34-positive cells, edited ex vivo with CRISPR-Cas9 and a corrective DNA template, and intended to be returned after conditioning. The article provides no dosing or prescribing instructions.
Clinical Best Practices
- The reported manufacturing process tests the edited, cryopreserved product before release.
- The study evaluated cell purity, viability, HBB correction, insertions or deletions, off-target editing, translocations, and karyotypes.
- Clinical safety, engraftment, and persistence are being assessed in the ongoing Phase I/II trial.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
